Results 121 to 130 of about 8,021,995 (282)
Myostatin/Smad3 in Spinal Muscular Atrophy: Biomarkers of Disease Severity and Treatment Response
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Given the role of Myostatin (MSTN) in muscle homeostasis and its modulation by current spinal muscular atrophy (SMA) therapies, we investigated serum MSTN and, for the first time, its downstream effector Smad3 as candidate non‐invasive biomarkers in SMA patients undergoing disease‐modifying therapies (DMTs).
Giorgia Riolo +11 more
wiley +1 more source
Tucker Center Newsletter Fall 2019
, 2019 Fall 2019 Newsletter. (2019). Tucker Center Newsletter Fall 2019.
core
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Blood‐based biomarkers are increasingly used to identify Alzheimer's disease (AD) pathology and may play an important role in early disease screening and participant selection for clinical trials. However, their performance across stages of cognitive impairment remains unclear. This study examined whether plasma biomarkers differ in
Maryam Abdolmaleki +7 more
wiley +1 more source
Discussiones Mathematicae Graph Theory, 2021 Ewa Drgas-Burchardt, Elzbieta Sidorowicz
openaire +2 more sources
Arthritis Care &Research, EarlyView.Objective Race and household income impact outcomes in patients with rheumatic conditions; however, their role in pediatric antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) remains poorly understood. We aimed to evaluate whether race and ethnicity and household income are associated with severe AAV disease and renal outcomes among
Roberto Alejandro Valdovinos +2 more
wiley +1 more source
, 2019 University of Minnesota Duluth. (2019). The Bark (2019-02).
University of Minnesota Duluth
core